TABLE 1.

Analysis of therapeutic combinations of AOP-RANTES and Met-SDF-1β at IC₉₅ and IC₉₉ in PBMC

Well no.	Drug condition	Viral isolate(s)	IC95 drug exposure		IC99 drug exposure
			HIV-1 p24 production (ng/ml)	% Inhibition	HIV-1 p24 production (ng/ml)	% Inhibition
1	Infected control	DK	60.2		87.9
2			60.5		102.0
3	Infected control	RM	70		63.4
4			60		51.3
5	Infected control	DK + RM	136		120.4
6			130.4		115.1
7	AOP-RANTES	RM	6	91	15.5	75
8			7	89	12.2	82
9	Met-SDF-1β	DK	0.4	99	3.7	99
10			0.4	99	6.3	99
11	AOP-RANTES + Met-SDF-1β	DK + RM	6.2	95	8.7	99
12			6	95	8.6	99
13	AOP-RANTES	DK + RM	83.3	37	66.5	46
14			97.7	27	23.9	85
15	Met-SDF-1β	DK + RM	69.4	48	63.2	49
16			75.5	43	30.6	79